From Drug Benefit News - Nearly a year after the last of the valid patents on Teva Pharmaceutical Industries Ltd.’s multiple sclerosis drug Copaxone (glatiramer acetate) expired, the FDA on April 16 cleared Sandoz Inc. and Momenta Pharmaceuticals, Inc. to market Glatopa, the first substitutable generic version of the daily injectable therapy. While entry of the generic has the potential to significantly lower costs in the multiple sclerosis category, there are several uncertainties that may impede successful penetration of the market, say industry insiders. Read more
From Specialty Pharmacy News - A confluence of events within the health care industry in 2014 — many of them tied to specialty medications — made it an exceptional year in many ways. Read more
From Specialty Pharmacy News - Following last month’s FDA approval of the first drug to take the abbreviated 351(k) biosimilar approval pathway, some of the unknown issues around these drugs have been addressed. Two weeks after the approval of Sandoz Inc.’s Zarxio (filgrastim-sndz) on March 6 (SPN 3/15, p. 1) came a decision in the lawsuit (Amgen Inc. et al v. Sandoz Inc. et al, Case No. 3:14-cv-04741-RS) brought by Amgen Inc., manufacturer of Neupogen (filgrastim),… Read more
Check out all of the benefits, sample issues & more!